Alex Agelidis

Alex Agelidis

Auto-generated profile, based on publicly available information

Alex Agelidis

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2015 in Nature Immunology
Verified
Journal Article
Open access
PDF file
MOMichio Onizawa
Michio Onizawa
SOShigeru Oshima
Shigeru Oshima
USUlf Schulze-Topphoff
Ulf Schulze-Topphoff
JOJuan A Oses-Prieto
Juan A Oses-Prieto
TLTimothy Lu
Timothy Lu
AMAveril Ma
Averil Ma
A20 is a deubiquitinating enzyme that restrict inflammation by various mechanisms. Ma and colleagues show that A20 inhibits necroptosis by inhibiting the ubiquitination of RIPK3 and formation of the RIPK1-RIPK3 complex. A20 is an anti-inflammatory protein linked to multiple human diseases; however, the mechanisms by which A20 prevents inflammatory disease are incompletely defined. We found that A20-deficient T cells and fibroblasts were susceptible to caspase-independent and kinase RIPK3–dependent necroptosis. Global deficiency in RIPK3 significantly restored the survival of A20-deficient mice. A20-deficient cells exhibited exaggerated formation of RIPK1-RIPK3 complexes. RIPK3 underwent physiological ubiquitination at Lys5 (K5), and this ubiquitination event supported the formation of RIPK1-RIPK3 complexes. Both the ubiquitination of RIPK3 and formation of the RIPK1-RIPK3 complex required the catalytic cysteine of A20's deubiquitinating motif. Our studies link A20 and the ubiquitination of RIPK3 to necroptotic cell death and suggest additional mechanisms by which A20 might prevent inflammatory disease.

1 January 2019 in The Ocular Surface
Verified
Journal Article
Closed access
ALAnn-Marie Lobo
Ann-Marie Lobo
AAAlex M. Agelidis
Alex M. Agelidis
DSDeepak Shukla
Deepak Shukla

28 October 2015 in Future Virology
Verified
Journal Article
Closed access
AAAlex M Agelidis
Alex M Agelidis
Deepak ShuklaDeepak Shukla
Deepak Shukla
HSV type-1 and -2 are widespread pathogens producing lifelong infection with multiple sequelae, including oral, ocular and genital disease. The process of herpesvirus entry is a highly complex process involving numerous viral and cellular factors. Entry begins with attachment of virus to the cell surface followed by interactions between viral glycoproteins and cellular receptors to facilitate capsid penetration. The nucleocapsid is then transported along microtubules to the nuclear membrane, where viral DNA is released for replication in the nucleus. The work reviewed here comprises the most recent advancements in our understanding of the mechanism involved in the herpesvirus entry process.

27 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHSatvik R. Hadigal
Satvik R. Hadigal
AAAlex M. Agelidis
Alex M. Agelidis
GKGhadah A. Karasneh
Ghadah A. Karasneh
TAThessicar E. Antoine
Thessicar E. Antoine
AYAbraam M. Yakoub
Abraam M. Yakoub
Deepak ShuklaDeepak Shukla
Deepak Shukla
Herpesviruses exemplified by herpes simplex virus-1 (HSV-1) attach to cell surface heparan sulfate (HS) for entry into host cells. However, during a productive infection, the HS moieties on parent cells can trap newly exiting viral progenies and inhibit their release. Here we demonstrate that a HS-degrading enzyme of the host, heparanase (HPSE), is upregulated through NF-kB and translocated to the cell surface upon HSV-1 infection for the removal of HS to facilitate viral release. We also find a significant increase in HPSE release in vivo during infection of murine corneas and that knockdown of HPSE in vivo inhibits virus shedding. Overall, we propose that HPSE acts as a molecular switch for turning a virus-permissive ‘attachment mode’ of host cells to a virus-deterring ‘detachment mode’. Since many human viruses use HS as an attachment receptor, the HPSE-HS interplay may delineate a common mechanism for virus release.

1 July 2017 in Cell Reports
Verified
Journal Article
Open access
AAAlex M. Agelidis
Alex M. Agelidis
SHSatvik R. Hadigal
Satvik R. Hadigal
DJDinesh Jaishankar
Dinesh Jaishankar
Deepak ShuklaDeepak Shukla
Deepak Shukla
Herpes simplex virus-1 (HSV-1) causes lifelong recurrent pathologies without a cure. How infection by HSV-1 triggers disease processes, especially in the immune-privileged avascular human cornea, remains a major unresolved puzzle. It has been speculated that a cornea-resident molecule must tip the balance in favor of pro-inflammatory and pro-angiogenic conditions observed with herpetic, as well as non-herpetic, ailments of the cornea. Here, we demonstrate that heparanase (HPSE), a host enzyme, is the molecular trigger for multiple pathologies associated with HSV-1 infection. In human corneal epithelial cells, HSV-1 infection upregulates HPSE in a manner dependent on HSV-1 infected cell protein 34.5. HPSE then relocates to the nucleus to regulate cytokine production, inhibits wound closure, enhances viral spread, and thus generates a toxic local environment. Overall, our findings implicate activated HPSE as a driver of viral pathogenesis and call for further attention to this host protein in infection and other inflammatory disorders.

14 February 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DJDinesh Jaishankar
Dinesh Jaishankar
AYAbraam M. Yakoub
Abraam M. Yakoub
TYTejabhiram Yadavalli
Tejabhiram Yadavalli
AAAlex Agelidis
Alex Agelidis
NTNeel Thakkar
Neel Thakkar
Deepak ShuklaDeepak Shukla
Deepak Shukla
A kinase inhibitor shows promise as a topical antiviral against ocular herpes.